**Supplementary Material**

**Expanded Patients and Methods**

Data on comorbidities/vascular risk factors are collected at baseline when patients are registered in the Danish Stroke Registry (DSR). Stroke severity was determined at admission and classified as a continuous variable according to the Scandinavian Stroke Scale (SSS) score. Furthermore, we categorized a score of 0 to 30 points as “severe stroke” and >30 as “less severe stroke” in the interaction analysis. Education was classified as low (primary and lower secondary education), medium (upper secondary, post-secondary non-tertiary, and short cycle tertiary education), or high (bachelor, master, and doctoral education) according to the International Standard Classification of Education. Income was grouped into tertiles as low, middle, and high. Occupation was categorized as employed, pensioner, or unemployed. Marital status was grouped as cohabiting, living alone, and other. Duration of residence was first handled as a continuous variable and subsequently categorized as <10 years and ≥10 years of residence among immigrants compared with Danish-born residents in the further analysis.

**Supplementary Table 1**. List of anatomical therapeutic chemical (ATC) codes included

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Class** | **ATC code** | **Prescription drug** | **Package** | **Average price per pack at the pharmacy in EUR** |
| Anticoagulants | B01AA03  B01AE07  B01AF01  B01AF02  B01AF03 | Warfarin (2.5 mg)  Dabigatran (75 mg)  Rivaroxaban (2.5 mg)  Apixaban (2.5 mg)  Edoxaban (30 mg) | 100 tablets  60 tablets  100 tablets  60 tablets  100 tablets | 18.77  97.89  121.09  90.05  227.40 |
| Antiplatelets | B01AC04  B01AC06  B01AC07 | Clopidogrel (75 mg)  Acetylsalicylic acid (75 mg)  Dipyridamole (100 mg) | 100 tablets  100 tablets  100 tablets | 8.97  5.11  23.91 |
| Angiotensin-converting enzyme inhibitors | C09AA01  C09AA02  C09AA03  C09AA05 | Captopril (25 mg)  Enalapril (10 mg)  Lisinopril (5 mg)  Ramipril (2.5 mg) | 100 tablets  100 tablets  100 tablets  100 tablets | 5.16  8.60  6.57  7.33 |
| Angiotensin II receptor blockers | C09CA01  C09CA03  C09CA06  C09CA07 | Losartan (100 mg)  Valsartan (160 mg)  Candesartan (4 mg)  Telmisartan (80 mg) | 100 tablets  100 tablets  100 tablets  100 tablets | 6.92  21.51  26.18  22.91 |
| Beta-blockers | C07AA05  C07AB02  C07AB03 | Propranolol (40 mg)  Metoprolol (25 mg)  Atenolol (25 mg) | 100 tablets  100 tablets  100 tablets | 4.53  5.44  8.14 |
| Calcium channel blockers | C08CA01  C08CA02  C08CA05  C08DA01 | Amlodipine (5 mg)  Felodipine (10 mg)  Nifedipine (30 mg)  Verapamil (80 mg) | 100 tablets  100 tablets  100 tablets  100 tablets | 5.58  6.75  28.30  15.94 |
| Statins | C10AA01  C10AA03  C10AA05  C10AA07 | Simvastatin (80 mg)  Pravastatin (20 mg)  Atorvastatin (40 mg)  Rosuvastatin (20 mg) | 100 tablets  100 tablets  100 tablets  100 tablets | 9.32  5.25  5.52  8.60 |

**Supplementary Table 2**. Use of preventive medications within 180 days after stroke discharge among immigrants compared with Danish-born residents

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | |  |  | **Region-Specific Immigrants** | | **Country-Specific Immigrants** | | | |
| **Danish-born**  **(n=101 777)** | **Immigrants**  **(n=4447)** | **Western**  **(n=2660)** | **Non-Western**  **(n=1787)** | **Polish**  **(n=178)** | **Turkish**  **(n=308)** | **Pakistani**  **(n=225)** | **Iraqi**  **(n=146)** |
| Anticoagulants |  |  |  |  |  |  |  |  |  |
| Use of medication | n (%) | 13 891 (13.6) | 539 (12.1) | 380 (14.3) | 159 (8.9) | 27 (15.2) | 31 (10.1) | 7 (3.1) | 14 (9.6) |
| Unadjusted | OR (95% CI) | 1.00 (Reference) | 0.88 (0.82−0.96) | 1.07 (0.98−1.18) | 0.61 (0.53−0.71) | 1.30 (0.92−1.84) | 0.75 (0.55−1.03) | - | 0.82 (0.51−1.33) |
| Fully adjusted | OR (95% CI) | 1.00 (Reference) | 0.66 (0.53−0.82) | 0.72 (0.55−0.95) | 0.58 (0.43−0.79) | 0.77 (0.35−1.67) | 0**.**50 (0.25−0.97) | - | 1.40 (0.68−2.88) |
| Antiplatelets |  |  |  |  |  |  |  |  |  |
| Use of medication | n (%) | 60 170 (59.1) | 2686 (60.4) | 1526 (57.4) | 1160 (64.9) | 89 (50.0) | 198 (64.3) | 164 (72.9) | 96 (65.8) |
| Unadjusted | OR (95% CI) | 1.00 (Reference) | 1.03 (0.99−1.08) | 0.97 (0.92−1.02) | 1.13 (1.06−1.20) | 0.74 (0.59−0.93) | 1.08 (0.93−1.26) | 1.14 (0.96−1.34) | 1.28 (1.01−1.63) |
| Fully adjusted | OR (95% CI) | 1.00 (Reference) | 1.04 (0.94−1.15) | 1.02 (0.89−1.16) | 1.06 (0.93−1.20) | 0.89 (0.61−1.30) | 1.11 (0.84−1.46) | 1.03 (0.78−1.35) | 1.07 (0.74−1.55) |
| ACE inhibitors/ARB |  |  |  |  |  |  |  |  |  |
| Use of medication | n (%) | 24 365 (23.9) | 1065 (23.9) | 631 (23.7) | 434 (24.2) | 40 (22.5) | 69 (22.4) | 65 (28.9) | 24 (16.4) |
| Unadjusted | OR (95% CI) | 1.00 (Reference) | 0.97 (0.92−1.03) | 0.99 (0.91−1.07) | 0.95 (0.87−1.05) | 0.95 (0.69−1.30) | 0.86 (0.68−1.08) | 1.01 (0.79−1.28) | 0.67 (0.44−1.01) |
| Fully adjusted | OR (95% CI) | 1.00 (Reference) | 0.87 (0.75−0.98) | 1.04 (0.86−1.26) | 0.74 (0.61−0.90) | 0.78 (0.43−1.41) | 0.45 (0.26−0.76) | 0.66 (0.42−1.03) | 0.51 (0.26−1.00) |
| Beta-blockers |  |  |  |  |  |  |  |  |  |
| Use of medication | n (%) | 13 822 (13.6) | 623 (14.0) | 373 (14.0) | 250 (14.0) | 37 (20.8) | 47 (15.3) | 44 (19.6) | 15 (10.3) |
| Unadjusted | OR (95% CI) | 1.00 (Reference) | 1.04 (0.96−1.13) | 1.06 (0.96−1.18) | 1.01 (0.89−1.14) | 1.82 (1.32−2.50) | 1.14 (0.87−1.50) | 1.22 (0.91−1.64) | 0.77 (0.46−1.30) |
| Fully adjusted | OR (95% CI) | 1.00 (Reference) | 1.25 (1.02−1.53) | 1.20 (0.92−1.56) | 1.30 (1.01−1.67) | 2.05 (1.12−3.75) | 1.88 (1.17−2.99) | 1.46 (0.86−2.50) | 1.16 (0.49−2.75) |
| Calcium channel blockers |  |  |  |  |  |  |  |  |  |
| Use of medication | n (%) | 17 739 (17.4) | 762 (17.1) | 451 (17.0) | 311 (17.4) | 24 (13.5) | 53 (17.2) | 44 (19.6) | 17 (11.6) |
| Unadjusted | OR (95% CI) | 1.00 (Reference) | 0.97 (0.90−1.04) | 1.00 (0.91−1.10) | 0.92 (0.82−1.03) | 0.85 (0.57−1.25) | 0.91 (0.69−1.19) | 0.88 (0.65−1.18) | 0.70 (0.43−1.14) |
| Fully adjusted | OR (95% CI) | 1.00 (Reference) | 0.94 (0.79−1.13) | 0.93 (0.73−1.18) | 0.95 (0.77−1.19) | 0.62 (0.30−1.29) | 0.49 (0.26−0.92) | 1.09 (0.70−1.69) | 0.96 (0.50−1.85) |
| Statins |  |  |  |  |  |  |  |  |  |
| Use of medication | n (%) | 52 058 (51.1) | 2338 (52.6) | 1339 (50.3) | 999 (55.9) | 93 (52.2) | 175 (56.8) | 153 (68.0) | 80 (54.8) |
| Unadjusted | OR (95% CI) | 1.00 (Reference) | 1.00 (0.96−1.05) | 0.98 (0.92−1.03) | 1.04 (0.98−1.12) | 1.07 (0.85−1.33) | 1.06 (0.91−1.25) | 1.15 (0.96−1.36) | 1.14 (0.88−1.47) |
| Fully adjusted | OR (95% CI) | 1.00 (Reference) | 1.08 (0.97−1.20) | 1.03 (0.89−1.18) | 1**.**12 (0.98−1.27) | 1.26 (0.88−1.82) | 1.32 (1.01−1.73) | 1.19 (0.89−1.59) | 1.14 (0.78−1.67) |

Abbreviations: OR = odds ratio; CI = confidence interval; ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blockers. The fully adjusted model composed age at stroke, sex, income, occupation, education, marital status, duration of residence, Scandinavian stroke scale (SSS) score, history of stroke or transient ischemic attack, smoking, myocardial infarction, atrial fibrillation, diabetes, and hypertension.

**Supplementary Table 3**. Factors associated with use of preventive medications after stroke discharge comparing immigrants and Danish-born residents

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Anti**  **coagulants** | **Fully adjusteda** | **Anti**  **platelets** | **Fully adjusteda** | **ACE inhibitors /ARB** | **Fully adjusteda** | **Beta-blockers** | **Fully adjusteda** | **Calcium channel blockers** | **Fully adjusteda** | **Statins** | **Fully adjusteda** |
| **n** | **OR (95% CI)** | **n** | **OR (95% CI)** | **n** | **OR (95% CI)** | **n** | **OR (95% CI)** | **n** | **OR (95% CI)** | **n** | **OR (95% CI)** |
| Education |  |  |  |  |  |  |  |  |  |  |  |  |
| Danish-born low education | 5968 | 1.00 (Reference) | 25 665 | 1.00 (Reference) | 10 454 | 1.00 (Reference) | 6218 | 1.00 (Reference) | 7846 | 1.00 (Reference) | 21 733 | 1.00 (Reference) |
| Immigrants low education | 137 | 0.60 (0.40─0.88) | 702 | 1.03 (0.87─1.23) | 281 | 0.74 (0.56─0.96) | 170 | 1.28 (0.91─1.81) | 216 | 0.99 (0.72─1.34) | 621 | 1.15 (0.96─1.38) |
| Danish-born high education | 1960 | 1.21 (0.92─1.58) | 7180 | 0.97 (0.84─1.12) | 2843 | 0.87 (0.71─1.07) | 1526 | 0.87 (0.64─1.17) | 2084 | 1.24 (0.97─1.58) | 6668 | 0.98 (0.85─1.14) |
| Immigrants high education | 85 | 0.89 (0.59─1.34) | 411 | 1.00 (0.82─1.21) | 160 | 0.89 (0.66─1.18) | 79 | 0.82 (0.51─1.31) | 118 | 1.21 (0.87─1.70) | 374 | 1.05 (0.85─1.29) |
| Income |  |  |  |  |  |  |  |  |  |  |  |  |
| Danish-born low income | 4269 | 1.00 (Reference) | 18 028 | 1.00 (Reference) | 7169 | 1.00 (Reference) | 4609 | 1.00 (Reference) | 5409 | 1.00 (Reference) | 14 079 | 1.00 (Reference) |
| Immigrants low income | 207 | 0.64 (0.43─0.94) | 986 | 1.02 (0.83─1.24) | 405 | 1.06 (0.79─1.42) | 254 | 1.19 (0.80─1.76) | 312 | 0.82 (0.58─1.17) | 808 | 1.10 (0.89─1.36) |
| Danish-born high income | 4686 | 0.82 (0.59─1.14) | 22 073 | 0.91 (0.77─1.08) | 9106 | 1.21 (0.94─1.56) | 4404 | 0.86 (0.59─1.23) | 6315 | 0.94 (0.70─1.26) | 20 511 | 1.12 (0.94─1.34) |
| Immigrants high income | 145 | 0.53 (0.34─0.82) | 780 | 0.96 (0.79─1.17) | 281 | 0.96 (0.71─1.30) | 177 | 1.24 (0.81─1.88) | 198 | 0.90 (0.63─1.27) | 727 | 1.22 (0.99─1.50) |
| Marital status |  |  |  |  |  |  |  |  |  |  |  |  |
| Danish-born living alone | 5591 | 1.00 (Reference) | 23 650 | 1.00 (Reference) | 9435 | 1.00 (Reference) | 5716 | 1.00 (Reference) | 7135 | 1.00 (Reference) | 19 425 | 1.00 (Reference) |
| Immigrants living alone | 221 | 0.77 (0.55─1.10) | 966 | 1.07 (0.90─1.28) | 387 | 0.88 (0.68─1.14) | 238 | 1.30 (0.91─1.85) | 305 | 0.86 (0.63─1.18) | 789 | 1.02 (0.85─1.23) |
| Danish-born cohabiting | 7789 | 1.11 (0.87─1.42) | 34 004 | 0.92 (0.81─1.05) | 14 110 | 1.00 (0.83─1.20) | 7593 | 1.27 (0.97─1.67) | 9976 | 0.97 (0.78─1.21) | 30 852 | 1.00 (0.87─1.14) |
| Immigrants cohabiting | 290 | 0.65 (0.48─0.88) | 1580 | 0.95 (0.82─1.09) | 616 | 0.88 (0.71─1.08) | 357 | 1.55 (1.16─2.08) | 417 | 0.92 (0.72─1.17) | 1445 | 1.13 (0.97─1.31) |
| Stroke severityb |  |  |  |  |  |  |  |  |  |  |  |  |
| Danish-born less severe stroke | 11 555 | 1.00 (Reference) | 53 931 | 1.00 (Reference) | 21 811 | 1.00 (Reference) | 12 003 | 1.00 (Reference) | 15 975 | 1.00 (Reference) | 47 318 | 1.00 (Reference) |
| Immigrants less severe stroke | 437 | 0.69 (0.54─0.87) | 2375 | 1.04 (0.94─1.16) | 949 | 0.91 (0.78─1.07) | 529 | 1.26 (1.02─1.57) | 661 | 0.93 (0.77─1.12) | 2094 | 1.04 (0.93─1.16) |
| Danish-born severe stroke | 2336 | 1.38 (0.97─1.96) | 6239 | 1.02 (0.82─1.26) | 2554 | 1.30 (0.98─1.73) | 1819 | 1**.**13 (0.75─1.70) | 1764 | 0.77 (0.51─1.16) | 4740 | 0.76 (0.61─0.96) |
| Immigrants severe stroke | 102 | 0.88 (0.58─1.34) | 311 | 0.98 (0.77─1.25) | 116 | 0.81 (0.56─1.17) | 94 | 1.34 (0.88─2.04) | 101 | 0.84 (0.54─1.31) | 244 | 1.11 (0.87─1.42) |
| Sex |  |  |  |  |  |  |  |  |  |  |  |  |
| Danish-born women | 7681 | 1.00 (Reference) | 33 224 | 1.00 (Reference) | 14 036 | 1.00 (Reference) | 7343 | 1.00 (Reference) | 9873 | 1.00 (Reference) | 29 361 | 1.00 (Reference) |
| Danish-born men | 6210 | 0.91 (0.71─1.16) | 26 946 | 1.00 (0.89─1.13) | 10 329 | 0.84 (0.70─1.00) | 6479 | 1.11 (0.85─1.43) | 7866 | 0.83 (0.67─1.04) | 22 697 | 1**.**14 (1.01─1.29) |
| Immigrant women | 255 | 0.60 (0.45─0.79) | 1435 | 1.08 (0.95─1.22) | 566 | 0.83 (0.69─0.98) | 327 | 1**.**25 (0.97─1.60) | 389 | 0.89 (0.72─1.10) | 1262 | 1.12 (0.98─1.28) |
| Immigrant men | 284 | 0.70 (0.51─0.96) | 1251 | 0.99 (0.85─1.15) | 499 | 0.81 (0.64─0.98) | 296 | 1**.**39 (1.03─1.88) | 373 | 0.89 (0.68─1.15) | 1076 | 1.15 (0.98─1.35) |
|  |  |  |  |  |  |  |  |  |  |  |  |  |

Abbreviations: OR = odds ratio; CI = confidence interval; n = number of patients; ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blockers. aThe fully adjusted model composed age at stroke, sex, income, occupation, education, marital status, duration of residence, Scandinavian stroke scale (SSS) score, history of stroke or transient ischemic attack, smoking, myocardial infarction, atrial fibrillation, diabetes, and hypertension. bStroke severity measured by the Scandinavian Stroke Scale score and 0 to 30 points was classified as “severe stroke” and >30 as “less severe stroke”.

**Supplementary Table 4.** Treatment persistence within 180 days follow-up comparing immigrants with Danish-born residents

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | |  |  | **Region-Specific Immigrants** | | **Country-Specific Immigrants** | | | |
| **Danish-born** | **Immigrants** | **Western** | **Non-Western** | **Polish** | **Turkish** | **Pakistani** | **Iraqi** |
| Anticoagulants |  |  |  |  |  |  |  |  |  |
| Treatment persistence | n (%) | 11 771 (84.7) | 458 (85.0) | 331 (87.1) | 127 (79.9) | 25 (92.6) | 22 (71.0) | 6 (85.7) | 12 (85.7) |
| Unadjusted | SHR (95% CI) | 1.00 (Reference) | 1.05 (0.96−1.14) | 1.10 (0.99−1.21) | 0.94 (0.80−1.10) | 1.07 (0.81−1.40) | 1.15 (0.76−1.73) | - | 1.32 (0.76−2.32) |
| Fully adjusted | SHR (95% CI) | 1.00 (Reference) | 1.21 (0.97−1.51**)** | 1.37 (1.06−1.78) | 1.04 (0.77−1.41) | 0.80 (0.54−1.22) | 1.25 (0.50−3.10) | - | 2.15 (0.75−5.13) |
| Antiplatelets |  |  |  |  |  |  |  |  |  |
| Treatment persistence | n (%) | 49 517 (82.3) | 2158 (80.3) | 1243 (81.5) | 915 (78.9) | 68 (76.4) | 150 (75.8) | 130 (79.3) | 69 (71.9) |
| Unadjusted | SHR (95% CI) | 1.00 (Reference) | 1.07 (1.03−1.12) | 1.06 (1.00−1.12) | 1.09 (1.03−1.16) | 0.93 (0.73−1.18) | 1.11 (0.96−1.29) | 1.03 (0.89−1.20) | 1.09 (0.88−1.34) |
| Fully adjusted | SHR (95% CI) | 1.00 (Reference) | 1.00 (0.91−1.10) | 0.97 (0.85−1.11) | 1.02 (0.91−1.15) | 0.83 (0.56−1.23) | 0.83 (0.64−1.08) | 0.92 (0.71−1.18) | 0.92 (0.67−1.26) |
| ACE inhibitors/ARB |  |  |  |  |  |  |  |  |  |
| Treatment persistence | n (%) | 19 789 (81.2) | 830 (77.9) | 505 (80.0) | 325 (74.9) | 37 (92.5) | 51 (73.9) | 56 (86.2) | 19 (79.2) |
| Unadjusted | SHR (95% CI) | 1.00 (Reference) | 0.99 (0.92−1.06) | 0.99 (0.92−1.08) | 0.98 (0.88−1.10) | 0.89 (0.70−1.15) | 1.25 (0.95−1.65) | 1.08 (0.83−1.40) | 1.35 (0.85−2.17) |
| Fully adjusted | SHR (95% CI) | 1.00 (Reference) | 1.01 (0.86−1.20) | 1.10 (0.91−1.33) | 0.93 (0.74−1.17) | 1.42 (0.83−2.41) | 0.90 (0.44−1.86) | 0.81 (0.49−1.35) | 1.96 (1.08−3.55) |
| Beta-blockers |  |  |  |  |  |  |  |  |  |
| Treatment persistence | n (%) | 11 221 (81.2) | 497 (79.8) | 301 (80.7) | 196 (78.4) | 30 (81.1) | 40 (85.1) | 34 (77.3) | 12 (80.0) |
| Unadjusted | SHR (95% CI) | 1.00 (Reference) | 1.07 (0.97−1.17) | 1.07 (0.95−1.21) | 1.07 (0.92−1.23) | 1.23 (0.86−1.74) | 1.13 (0.84−1.52) | 1.13 (0.77−1.65) | 1.17 (0.69−1.99) |
| Fully adjusted | SHR (95% CI) | 1.00 (Reference) | 1.08 (0.86−1.35) | 1.09 (0.82−1.44) | 1.07 (0.80−1.43) | 1.34 (0.95−1.90) | 0.92 (0.53−1.60) | 0.99 (0.48−2.01) | 0.55 (0.20−1.51) |
| Calcium channel blockers |  |  |  |  |  |  |  |  |  |
| Treatment persistence | n (%) | 14 186 (80.0) | 589 (77.3) | 353 (78.3) | 236 (75.9) | 21 (87.5) | 38 (71.7) | 32 (72.7) | 13 (76.5) |
| Unadjusted | SHR (95% CI) | 1.00 (Reference) | 1.04 (0.95−1.12) | 1.03 (0.93−1.14) | 1.04 (0.91−1.18) | 1.50 (0.95−2.39) | 1.15 (0.79−1.69) | 0.86 (0.65−1.16) | 1.04 (0.62−1.74) |
| Fully adjusted | SHR (95% CI) | 1.00 (Reference) | 1.01 (0.81−1.26) | 1.00 (0.76−1.33) | 1.02 (0.79−1.32) | 1.65 (0.81−3.35) | 0.75 (0.29−1.92) | 0.91 (0.53−1.54) | 0.51 (0.19−1.34) |
| Statins |  |  |  |  |  |  |  |  |  |
| Treatment persistence | n (%) | 43 419 (83.4) | 1896 (81.1) | 1125 (84.0) | 771 (77.2) | 71 (76.3) | 125 (71.4) | 118 (77.1) | 57 (71.3) |
| Unadjusted | SHR (95% CI) | 1.00 (Reference) | 1.04 (0.99−1.09) | 1.05 (0.98−1.11) | 1.04 (0.96−1.12) | 1.05 (0.85−1.29) | 1.10 (0.90−1.33) | 1.01 (0.86−1.20) | 0.97 (0.75−1.26) |
| Fully adjusted | SHR (95% CI) | 1.00 (Reference) | 0.96 (0.86−1.07) | 0.94 (0.82−1.07) | 0.99 (0.86−1.14) | 1.01 (0.70−1.43) | 0.83 (0.59−1.16) | 1.02 (0.78−1.32) | 0.77 (0.49−1.22) |

Abbreviations: SHR = subhazard ratio; CI = confidence interval; ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blockers; n = number of patients. Western immigrants include Swedish, Norwegian, Finnish, German, Polish and British immigrants**.** Non-Westernimmigrants include Turkish, Former Yugoslavian, Iraqi, Iranian,and Pakistani immigrants. The fully adjusted model composed age at stroke, sex, income, occupation, education, marital status, duration of residence, Scandinavian stroke scale (SSS) score, history of stroke or transient ischemic attack, smoking, myocardial infarction, atrial fibrillation, diabetes, and hypertension.

**Supplementary Table 5**. Use and persistence of anticoagulants in patients with ischemic stroke and atrial fibrillation by region and country of origin


|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Use of**  **anticoagulants** | **Unadjusted** | **Fully adjusted** | **Persistence of**  **anticoagulants** | **Unadjusted** | **Fully adjusted** |
| **n** | **OR (95% CI)** | **OR (95% CI)** | **n** | **SHR (95% CI)** | **SHR (95% CI)** |
| Danish-born | 8247 | 1.00 (Reference) | 1.00 (Reference) | 6990 | 1.00 (Reference) | 1.00 (Reference) |
| Immigrants | 331 | 0.95 (0.84−1.06) | 0.93 (0.66−1.31) | 282 | 1.09 (0.97−1.21) | 0.92 (0.65−1.31) |
| Western | 246 | 0.95 (0.83−1.08) | 1.03 (0.70−1.50) | 217 | 1.17 (1.00−1.33) | 1.11 (0.78−1.60) |
| Non-Western | 85 | 0.96 (0.76−1.19) | 0.77 (0.47−1.27) | 65 | 0.86 (0.69−1.08) | 0.61 (0.35−1.04) |
| Polish | 18 | 0.91 (0.55−1.50) | 1.03 (0.34−3.10) | 16 | 1.12 (0.78−1.60) | 0**.**52 (0.27−1.01) |
| Turkish | 20 | 1.06 (0.68−1.64) | 0.68 (0.24−1.91) | 15 | 1.13 (0.70−1.79) | 0.83 (0.23−2.94) |

Abbreviations: OR = odds ratio; SHR = subhazard ratios; CI = confidence interval. The fully adjusted model composed age at stroke, sex, income, occupation, education, marital status, duration of residence, Scandinavian stroke scale (SSS) score, history of stroke or transient ischemic attack, smoking, myocardial infarction, diabetes, and hypertension.


**Supplementary Table 6.** Use and persistence of secondary preventive medications by duration of residence

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Use of**  **medication** | **Unadjusted** | **Fully adjusted** | **Persistence of**  **medication** | **Unadjusted** | **Fully adjusted** |
| **n** | **OR (95% CI)** | **OR (95% CI)** | **n** | **SHR (95% CI)** | **SHR (95% CI)** |
| **Anticoagulants** |  |  |  |  |  |  |
| Danish-born | 13 891 | 1.00 (Reference) | 1.00 (Reference) | 11 771 | 1.00 (Reference) | 1.00 (Reference) |
| Immigrants (≥10 years of residence) | 246 | 0.98 (0.97−0.99) | 0.75 (0.63−0.90) | 210 | 1.06 (0.94−1.20) | 1.21 (0.97-1.51) |
| Immigrants (<10 years of residence) | 14 | 0.94 (0.92−0.97) | a | 12 | 1.00 (0.70−1.43) | a |
| **Antiplatelets** |  |  |  |  |  |  |
| Danish-born | 60 170 | 1.00 (Reference) | 1.00 (Reference) | 49 517 | 1.00 (Reference) | 1.00 (Reference) |
| Immigrants (≥10 years of residence) | 1507 | 1.02 (1.01−1.03) | 1.08 (1.00−1.17) | 1203 | 1.06 (1.01−1.12) | 1.00 (0.91−1.10) |
| Immigrants (<10 years of residence) | 107 | 1.08 (1.03−1.13) | 1.09 (0.67−1.77) | 93 | 1.19 (0.97−1.46) | 1.10 (0.72−1.69) |
| **ACE inhibitors/ARB** |  |  |  |  |  |  |
| Danish-born | 24 365 | 1.00 (Reference) | 1.00 (Reference) | 19 789 | 1.00 (Reference) | 1.00 (Reference) |
| Immigrants (≥10 years of residence) | 554 | 0.99 (0.98−1.00) | 0.88 (0.78−1.00) | 439 | 1.02 (0.93−1.11) | 1.01 (0.86−1.20) |
| Immigrants (<10 years of residence) | 38 | 0.99 (0.96−1.02) | 1.40 (0.76−2.57) | 31 | 1.10 (0.74−1.61) | 1.14 (0.66−1.97) |
| **Beta-blockers** |  |  |  |  |  |  |
| Danish-born | 13 822 | 1.00 (Reference) | 1.00 (Reference) | 11 221 | 1.00 (Reference) | 1.00 (Reference) |
| Immigrants (≥10 years of residence) | 328 | 1.00 (0.99−1.01) | 1.13 (0.98−1.33) | 267 | 1.11 (0.98−1.26) | 1.07 (0.86−1.34) |
| Immigrants (<10 years of residence) | 20 | 0.98 (0.95−1.00) | 0.51 (0.13−2.10) | 15 | 1.39 (0.89−2.17) | a |
| **Calcium channel blockers** |  |  |  |  |  |  |
| Danish-born | 17 739 | 1.00 (Reference) | 1.00 (Reference) | 14 186 | 1.00 (Reference) | 1.00 (Reference) |
| Immigrants (≥10 years of residence) | 394 | 0.99 (0.98−1.00) | 0.93 (0.81−1.07) | 301 | 1.10 (0.99−1.23) | 1.01 (0.82−1.26) |
| Immigrants (<10 years of residence) | 25 | 0.99 (0.97−1.02) | 1.21 (0.58−2.54) | 19 | 0.87 (0.59−1.29) | 1.08 (0.48−2.44) |
| **Statins** |  |  |  |  |  |  |
| Danish-born | 52 508 | 1.00 (Reference) | 1.00 (Reference) | 43 419 | 1.00 (Reference) | 1.00 (Reference) |
| Immigrants (≥10 years of residence) | 1292 | 1.01 (0.99−1.02) | 1.03 (0.95−1.12) | 1024 | 1.01 (0.95−1.08) | 0.97 (0.87−1.08) |
| Immigrants (<10 years of residence) | 92 | 1.00 (0.96−1.05) | 0.91 (0.54−1.55) | 80 | 1.20 (0.95−1.50) | 0.75 (0.57−1.02) |

Abbreviations: OR = odds ratio; SHR = subhazard ratios; CI = confidence interval; n = number of patients; ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blockers. aEstimates could not be produced due to small numbers. Fully adjusted model composed age at stroke, sex, income, occupation, education, marital status, duration of residence, stroke severity, history of stroke or transient ischemic attack, smoking, myocardial infarction, atrial fibrillation, diabetes, and hypertension.

****

**Supplementary Figure 1.** Average price per pack on dispensed medications in patients with ischemic stroke. Higher prices of anticoagulants from 2011 onwards is due to introduction of novel oral anticoagulants.

****

**Supplementary Figure 2.** Use of at least one of the preventive medications by region of origin